GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptamer Group PLC (LSE:APTA) » Definitions » ROCE %

Aptamer Group (LSE:APTA) ROCE % : -196.72% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Aptamer Group ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Aptamer Group's annualized ROCE % for the quarter that ended in Dec. 2023 was -196.72%.


Aptamer Group ROCE % Historical Data

The historical data trend for Aptamer Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptamer Group ROCE % Chart

Aptamer Group Annual Data
Trend Mar19 Mar20 Jun22 Jun23
ROCE %
-63.94 -152.76 -54.90 -159.24

Aptamer Group Semi-Annual Data
Mar19 Mar20 Dec21 Jun22 Dec22 Jun23 Dec23
ROCE % Get a 7-Day Free Trial -49.63 -31.73 -74.83 -279.37 -196.72

Aptamer Group ROCE % Calculation

Aptamer Group's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2023 )  (A: Jun. 2022 )(A: Jun. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2023 )  (A: Jun. 2022 )(A: Jun. 2023 )
=-8.166/( ( (11.52 - 2.374) + (2.753 - 1.643) )/ 2 )
=-8.166/( (9.146+1.11)/ 2 )
=-8.166/5.128
=-159.24 %

Aptamer Group's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=-3.722/( ( (2.753 - 1.643) + (3.968 - 1.294) )/ 2 )
=-3.722/( ( 1.11 + 2.674 )/ 2 )
=-3.722/1.892
=-196.72 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aptamer Group  (LSE:APTA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Aptamer Group ROCE % Related Terms

Thank you for viewing the detailed overview of Aptamer Group's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptamer Group (LSE:APTA) Business Description

Traded in Other Exchanges
Address
Innovation Way, Windmill House, York, GBR, YO10 5BR
Aptamer Group PLC provides Optimer binders for use in research, diagnostics and therapeutics. It strives to deliver transformational solutions that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer technology. Its businesses: Aptamer Solutions for custom Optimer development, Aptamer Diagnostics for in-house and collaborative Optimer-based diagnostic development and Aptamer Therapeutics for the development of Optimer-based therapeutics.

Aptamer Group (LSE:APTA) Headlines

No Headlines